The Institute mainly applies new and effective Cas9 gene-targeting technologies optimized by the team to produce patient-derived tumor immunology target-gene models that are urgently needed by the market. At present, it has established three major service platforms including a creation platform for patient-derived models for drug screenings, an open drug-screening service platform based on patient-derived models, and a development and production platform for patient-derived drug research into monoclonal antibodies (mAbs). The Institute currently has more than 90 kinds of patient-derived disease model strains with independent intellectual property rights and has established more than 100 strains under study in research projects.
Contact number: +86 (0) 25 58265927
Address: No. 12 Xuefu Road, Jiangbei New Area, Nanjing
Official website: www.gempharmatech.com